Virpax Pharmaceuticals, Inc. (VRPX)
| Market Cap | 124.00 -99.1% |
| Revenue (ttm) | n/a |
| Net Income | -12.07M |
| EPS | -70.91 |
| Shares Out | 1.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.1000 |
| Beta | -16.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug produ... [Read more]
Financial Performance
Financial StatementsNews
Virpax Pharmaceuticals Inc trading halted, news pending
19:50 EDT Virpax Pharmaceuticals (VRPX) Inc trading halted, news pending
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
Virpax Pharmaceuticals (VRPX) announced that it will effect a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share that will become effective at 12:01 a.m. Eastern…
Virpax Pharmaceuticals Announces Reverse Stock Split
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic st...
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals (VRPX) announced positive results from a beagle dog dose range finding study. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to...
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic...
Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
16:36 EDT Virpax Pharmaceuticals (VRPX) files to sell common stock and warrants, no amount given
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax's NES100 to be Presented at The Society of Toxicology by NCATS
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data
The company states: “Virpax Pharmaceutical would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology and showing no moderate to severe adverse events. V...
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
Virpax Pharmaceuticals (VRPX) announced the completion of the full study that followed the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research, USAISR, under an exis...
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering
NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement ...
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals announces results from Probudur minipig DRF study
Virpax Pharmaceuticals (VRPX) announced results from a minipig dose range finding, or DRF, study for Probudur. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wou...
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax Pharmaceuticals announces HHS pact over NES100 developmental extension
Virpax Pharmaceuticals (VRPX) announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences, an in...
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that ...
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceutical...
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals downgraded to Hold from Buy at Maxim
Maxim downgraded Virpax Pharmaceuticals to Hold from Buy.
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.